Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
336. |
ECCT/23/03/02 | Sunrise-3 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 |
Principal Investigator(s) 1. Dr. Paul Yonga 2. Dr John Kinuthia 3. DR LUCAS OTIENO TINA Site(s) in Kenya 1. Fountain Projects and Research Office, Clinical Research Centre (FOPRO-CRC) (Kisumu county) 2. KENYATTA NATIONAL HOSPITAL (Nairobi City county) 3. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
View |
337. |
ECCT/21/10/05 | Lactolize Study Lactoferrin and Lysozyme supplementation for long-term diarrhea sequelae |
Principal Investigator(s) 1. Benson Ochieng Singa Site(s) in Kenya 1. Awendo Sub-County Hospital (Migori county) 2. Homa Bay County Referral Hospital (Homa Bay county) 3. Isebania Sub-County Hospital (Migori county) 4. Kendu Adventist Hospital (Homa Bay county) 5. Kisii Teaching and Referral Hospital (Kisii county) 6. Mbita Sub-County Hospital (Homa Bay county) 7. Rongo Sub-County Hospital (Migori county) |
View |
338. |
ECCT/20/09/06 | Schisto RDT evaluation A performance evaluation of a prototype rapid diagnostic test for the diagnosis of schistosomiasis |
Principal Investigator(s) 1. Sammy Njenga Site(s) in Kenya Kenya Medical Research Institute (KEMRI) |
View |
339. |
ECCT/17/06/01 | MF/PM Phase III An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stibogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa |
Principal Investigator(s) 1. Jane Mbui Site(s) in Kenya 1. Kimalel Health Centre (Baringo county) 2. Kacheliba sub-county hospital (West Pokot county) |
View |
340. |
ECCT/15/04/02 | Plasma concentration profiles after oral administration of oleylphosphocholine tablet formulation: safety, tolerability and pharmacokinetics of 100 mg single dose in healthy male volunteers. |
Principal Investigator(s) 1. Ravasco Rashid Juma Site(s) in Kenya KEMRI |
View |